Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis

Keyphrases

• Myasthenia Gravis 100%
• Acetylcholine Receptor Antibody 100%
• Complement C5 Inhibitor 100%
• Zilucoplan 100%
• Complement Cascade 28%
• Etiology 14%
• Therapeutic Potential 14%
• Neuromuscular Junction 14%
• Acetylcholine Receptor (AChR) 14%
• Placebo-controlled 14%
• Clinically Significant 14%
• Randomized Double-blind 14%
• Safety Self-efficacy 14%
• Tolerability 14%
• Autoimmune Disease 14%
• Safety Data 14%
• Efficacy Data 14%
• Current Treatment 14%
• Immune System 14%
• Life-threatening 14%
• Side Effect Profile 14%
• Tissue Damage 14%
• Muscle Weakness 14%
• Membrane Attack Complex 14%
• Pathogenic Role 14%
• Phase II Clinical Trial 14%
• Treatment Paradigms 14%
• Pharmacokinetics-pharmacodynamics (PK-PD) 14%
• Cyclic Peptide 14%
• Targeted Treatment 14%
• Causal Mechanisms 14%
• Complement Component 5 14%
• Complement Inhibition 14%
• Peptide Targeting 14%
• Macrocyclic Peptides 14%
• Pathogenic Autoantibodies 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Cholinergic Receptor 100%
• Autoantibodies 100%
• Myasthenia gravis 100%
• Complement Component C5 Inhibitor 100%
• Zilucoplan 100%
• Side Effect 14%
• Placebo 14%
• Tissue Injury 14%
• Clinical Trial 14%
• Tolerability 14%
• Pharmacokinetics 14%
• Pharmacodynamics 14%
• Autoimmune Disease 14%
• Complement Membrane Attack Complex 14%
• Cyclopeptide 14%
• Muscle Weakness 14%
• Complement Component C5 14%